XtalPi
From Wikipedia, the free encyclopedia
 | |
Native name | 晶泰控股有限公司 |
|---|---|
| Formerly | QuantumPharm |
| Company type | Public |
| SEHK: 2228 | |
| Industry | |
| Founded | 2015 |
| Founders |
|
| Headquarters | Shenzhen, Guangdong, China |
Key people |
|
| Revenue |  CN¥174.42 million (2023) |
 CN¥−1.91 billion (2023) | |
| Total assets | CN¥4.01 billion (2023) |
| Total equity | CN¥−7.42 billion (2023) |
Number of employees | 783 (2023) |
| Website | xtalpi |
| Footnotes / references [1] | |
XtalPi Holdings Limited (XtalPi; Chinese: 晶泰科技; pinyin: Jīngtài Kējì) is a publicly listed Chinese biotechnology company that engages in research and development for early-stage drug discovery and material science through methods backed by artificial intelligence (AI).
In 2015, XtalPi was founded in China by Wen Shuhao, Ma Jian and Lai Lipeng. The three co-founders are quantum physicists who previously worked as postdoctoral researchers at the Massachusetts Institute of Technology. The companies applied quantum algorithms to drug development. At the time it was one of the very few AI drug discovery companies in Asia which quickly drew investor interest. XtalPi claimed to be the world's most well-funded startup in the space with its investors including Tencent, 5Y Capital, Google, Susquehanna International Group, Sino Biopharmaceutical and SoftBank Vision Fund.[2][3][4]
In 2022, after working with pharmaceutical companies like Eli Lilly, Johnson & Johnson and Merck & Co., XtalPi looked towards expanding into material science where it could apply its services. Most notably solar panels and electric vehicle batteries.[2][5]
In June 2024, XtalPi helds its initial public offering and became a listed company on the Hong Kong Stock Exchange.The offering raised HK$989.3 million ($126.7 million) and on the first day of trading, the shares rose 9.8%. XtalPi was the first company to go public under the 18C rule for specialist technology companies with smaller market cap and lower revenue.[3]
In February 2025, XtalPi announced it will raise HK$2.08 billion ($267 million) through a share placement. It also stated that one of its subsidiaries will work with Hengjian Holding to gear up the company's "AI+ Technology and Industry Integration Innovation Consortium Project" in the Greater Bay Area.[6]
In April 2025 during CCP General Secretary Xi Jinping's visit to Shanghai, XtalPi held a meeting with him to present its commitment to scientific and technological self-reliance.[7]
In August 2025, XtalPi announced it signed a US$6 billion deal with DoveTree, a firm established by Gregory L. Verdine.[8]
On 10 April 2026, Ailux, the AI-biotech subsidiary of XtalPi, appointed Maria Belvisi as its Chief Scientific Officer.[9]